Anxiety

South Carolina

21 Anxiety Trials near South Carolina

Power is an online platform that helps thousands of Anxiety patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication
SuperSite
This Phase 2/3 clinical trial is designed to evaluate SEP-363856 for Generalized Anxiety Disorder
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18 - 65

434 Participants Needed

Active on Power

MM120-300 for Anxiety

Savannah, Georgia
The reason for this study is to see if the investigational study drug, called MM120, can help people with Anxiety compared to a placebo. A placebo is an inactive drug that looks like MM120 but does not contain any active ingredients.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

198 Participants Needed

Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs. ABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or Placebo in addition to their currently prescribed ADTs. There is 1 in 3 chance of participants assigned to Placebo. Approximately 315 adult participants with GAD and inadequate response to ADTs will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 or matching placebo in addition to their prescribed ADT for 6 weeks and then will be followed for an additional 4 week follow-up period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Stay on current meds

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65

315 Participants Needed

This trial is testing a new medication called ENX-102 to see if it can help people with generalized anxiety disorder by reducing their anxiety symptoms.

Trial Details

Trial Status:Recruiting
Age:18 - 65

280 Participants Needed

This is a study to find out if a cutting-edge technology called transcranial focused ultrasound (tFUS) can be used to treat how people with anxiety or related concerns cope with emotional situations. tFUS is a brain stimulation technology that causes temporary changes in the activity of deep brain areas without a need for any surgery or other permanent or invasive procedures. This study is recruiting participants who recently started treatment for anxiety or a related concern to come in for 3 visits at the Medical University of South Carolina. At the first visit, participants will do interviews and surveys asking about anxiety and related concerns, and they do tasks where they respond to emotional pictures while brain activity is measured using magnetic resonance imaging (MRI). At the next two visits, participants again do a task where they see and react to emotional images, and this time the task is done once before and again once after receiving tFUS that either actively causes temporary changes (lasting for about an hour) in a targeted brain area or is not active (no changes elicited). At each tFUS visit, responses are measured with sensors worn on the hand, arms, face, and head (these visits do not involve MRI). Each visit in this study is expected to last between 2 - 3 hours. This study is not a treatment study, but it could help improve treatment in the future. Participants in this study are paid for their time.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

40 Participants Needed

rTMS for Anxiety Disorders

Charleston, South Carolina
This trial is testing if a device called rTMS, which uses magnetic fields to stimulate the brain, can help people cope better with fear and anxiety. The magnetic field increases brain activity, which might improve their responses to anxiety-inducing situations. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain and has been explored for treating various psychiatric disorders, including depression and anxiety.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

80 Participants Needed

This is a double-blind study to evaluate the efficacy and safety of ENX-102 in participants with social anxiety disorder (SAD).

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

220 Participants Needed

Social anxiety is associated with significant deficits in social and occupational functioning. The proposed study seeks to evaluate the feasibility of implementing a brief text-based intervention for decreasing social anxiety related safety behaviors among Veterans attempting to re-integrate into the workforce. Findings from this pilot will support a larger randomized controlled study examining the efficacy of the intervention for improving functional outcomes and quality of life among Veterans.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

30 Participants Needed

Cognitive behavioral therapy (CBT) is a brief, efficient, and effective treatment for individuals with depressive/anxiety disorders. However, CBT is largely underutilized within the Department of Veterans Affairs due to the cost and burden of trainings necessary to deliver all of the related disorder-specific treatments (DSTs). Transdiagnostic Behavior Therapy (TBT), in contrast, is specifically designed to address numerous distinct disorders within a single protocol in Veterans with depressive/anxiety disorders. The proposed research seeks to evaluate the efficacy of TBT by assessing psychiatric symptomatology and related impairment outcomes in Veterans with social anxiety disorder and comorbid posttraumatic stress via a randomized controlled trial of TBT and an existing DST. Assessments will be completed at pre-, mid-, and post-treatment, and at 6-month follow-up. Process variables also will be investigated.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

264 Participants Needed

Stigma and discrimination related to HIV and AIDS ("HIV-related stigma") have been identified worldwide as major barriers to HIV treatment and care, posing challenges to HIV prevention efforts and provision of adequate care, support, and treatment. Despite decades of global efforts to tackle HIV-related stigma, previous interventions designed to reduce stigma have been largely ineffective. The knowledge gaps and challenges for combating HIV-related stigma are partly rooted in the complexity and diversity of the stigma and partly in the limitations in current conceptualization of stigma reduction efforts. Recent research, including our own preliminary data, has shown the promise of resilience approaches that focus on the development of strengths, competencies, resources, and capacities of people living with HIV (PLWH) and those of their real or surrogate family members and healthcare facilities to prevent, reduce, and mitigate the negative effects of stigma. However, the resilience approach, while hypothesized, has not been widely tested in intervention trials. In the current application, we propose to develop, implement, and evaluate a theory-guided, multilevel multimode resilience-based intervention via a stepped-wedge randomized trial among 800 PLWH and their real or surrogate family members as well as 320 healthcare providers in Guangxi, China where we have built a strong research infrastructure and community collaboration through NIH-funded research since 2004. The primary outcome will be viral suppression among PLWH, and the intermediate outcomes will include resilience resources at the levels of individuals, the real or surrogate family members, and healthcare facilities as well as chronic stress response and adherence to treatment and care. The proposed study is innovative as it addresses a number of knowledge gaps in HIV-related stigma reduction intervention research based on both a conceptualization of stigma reduction and advancement in intervention research methodology (e.g., multilevel and multi-component intervention modality, a stepped wedge design, the addition of biomarkers to assess the effects of stigma, and targeting primary HIV clinical outcomes such as viral suppression). The proposed research is significant as it addresses a critical public health issue in the US and globally. The proposed intervention protocol, if proven efficacious, has the potential to be replicated in other low- and middle-income countries to mitigate the negative impact of stigma on the HIV treatment and care continuum.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

1928 Participants Needed

High-Dose rTMS for Depression

Charleston, South Carolina
High frequency repetitive transcranial magnetic stimulation (rTMS) has been shown to be safe, feasible, and acceptable. Conventionally, rTMS investigations have relied on rational decision trees for dosage determination. The purpose of this study is to systematically examine an accelerated protocol of intermittent theta burst (iTBS). Study 1 aims to provide a quantifiable dose-response curve for iTBS and depressive symptom reduction in major depression. Study 2 aims to determine the role of individual variations of their functional networks compared to the site of stimulation and clinical outcomes.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 60

70 Participants Needed

Investigators will recruit up to 10 patients with Anxiety comorbid with Autism Spectrum Disorder (ASD) from the outpatient clinics at MUSC. This pilot trial will be an open-label investigation of the safety and feasibility of transcutaneous auricular vagus nerve stimulation (taVNS) as a nonpharmacological wearable intervention used to manage anxiety and other neuropsychiatric symptoms at home, with patients/caretakers self-administering treatments. Each subject will undergo an initial in-person screening and be consented prior to participating in the study. This will be followed by an in-person training session with the subject (and caretaker if applicable), where they will learn how to self-administer taVNS and ask any pertinent questions. Participants will self-administer taVNS at home twice daily for 4 weeks. These treatments will not interfere with other aspects of their mental health care. Our investigators, over the prior 8 years, have demonstrated that taVNS is safe and feasible in the outpatient setting. Furthermore, investigators have recently demonstrated that taVNS is well tolerated and safely self-administered at home with remote monitoring. The investigators hypothesize that taVNS will be safe and feasible to administer at home in this new population. Results from this study may lead to further exploration of taVNS in this unique population.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 17

10 Participants Needed

This efficacy trial will evaluate the impact of an enhanced version of the Interconnected Systems Framework (ISFE) on elementary school-based team functioning, including use of evidence-based practices, and student emotional, behavioral, and academic functioning. The original interconnected systems framework (ISF) model was designed to improve the depth and quality of mental health services delivered within multi-tiered systems of support by integrating Positive Behavioral Interventions and Supports (PBIS) and school mental health (SMH) efforts to provide a continuum of high-quality services for students. Preliminary findings from a prior efficacy study show that the ISF improved team functioning and increased identification and services for students in need, particularly among youth of color, when compared to the other two conditions. Moreover, the ISF led to improvements in student social, emotional, and behavioral functioning. The current study builds on these findings by testing an enhanced version of the ISF designed to advance the model by adding/modifying several core components intended to further increase the impacts for youth with significant emotional and behavioral problems and reduce inequities in discipline and student service delivery.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased

1208 Participants Needed

The goal of this clinical trial is to assess whether the presence of a certified therapy dog during dental procedures that require an injection reduces anxiety and improves behavior in pediatric dental patients. The main questions it aims to answer are: * Does the presence of a certified therapy dog during dental procedure requiring an injection reduce anxiety and improve behavior in pediatric dental patients? * How do the parents of pediatric dental patients who participate in the study view the use of a certified therapy dog in their child's treatment? * Does the presence of a certified therapy dog result in different concentrations of microbes in the treatment room? All participants will receive standard of care. Researchers will compare the group with a therapy dog present to a group who does not have a therapy dog present to see if heart rate, oxygen saturation, percentage of nitrous oxide administered, and Frankl scores differ between the groups.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:3 - 7

70 Participants Needed

The purpose of the study is to compare a text message-based mental health and substance use screening and referral to a treatment program, called Listening to Women and Pregnant and Postpartum People (LTWP), to standard of care in-person mental health and substance use screening to look at rates of treatment attendance and retention in treatment. Participation would involve completing online questionnaires. You may be eligible to participate if you are age 18-45 years, are pregnant and entering prenatal care in one of MUSC's OB clinics, and attended a prenatal appointment at an MUSC clinic.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 45
Sex:Female

10473 Participants Needed

Virtual Reality for Hospice Care

Seneca, South Carolina
Background: Nature-based virtual reality (VR) and other outdoor experiences in head-mounted displays (HMDs) offer powerful, non-pharmacological tools for hospice teams to help patients undergoing end-of-life (EOL) transitions. However, the psychological distress of the patient-caregiver dyad is interconnected and highlights the interdependence and responsiveness to distress as a unit. Hospice care services and healthcare need strategies to help patients and informal caregivers with EOL transitions.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

11 Participants Needed

Mobile TMS for Depression

Charleston, South Carolina
In this pilot study, investigators propose to design and create a portable TMS unit, in a van, and then test out delivering TMS in three different locations in South Carolina, all affiliated with MUSC and within 2-hours driving from Charleston, SC. This study would test out this new delivery mode, and provide valuable feasibility, safety, and efficacy lessons for later refinement and potential widespread adoption of mobile TMS as a treatment option, both in our state and across the US.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:22 - 80

30 Participants Needed

This study involves testing how useful a technology-enhanced therapy is for pregnant people prescribed buprenorphine for the treatment of opioid use disorder, compared to medication monitoring. Participants are randomized to one of the conditions. If participants are randomized to receive the therapy, participants will attend four 60-minute therapy appointments during pregnancy with an additional 30-minute therapy session towards the end of pregnancy, and 6 additional monthly postpartum (after childbirth) sessions (0-6 months postpartum). As part of the therapy program, participants will receive access to a mobile application, which will be accessible for the duration of the study. If participants are randomized to medication monitoring, participants will be asked to log each time participants take their medication for two months. All participants will also be asked to complete questionnaires at enrollment and again at 3-month postpartum and 6-months postpartum, and will be contacted randomly throughout the study to perform a medication count. The total duration of the study is between 8-12 months depending on when participants enroll (early second trimester-mid third trimester).
Stay on current meds
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 45
Sex:Female

37 Participants Needed

The purpose of this study is to explore whether a non-invasive form of ear stimulation called transcutaneous auricular vagus nerve stimulation (taVNS) can manage symptoms in patients with autism spectrum disorder (ASD). Additionally, this study also uses magnetic resonance imaging (MRI) to capture images of participants' brains and apply an image processing method called INSCAPE to track brain state changes during taVNS treatment in ASD. Investigators will recruit up to 16 participants with ASD.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 17

16 Participants Needed

This study involves testing how useful a technology-enhanced intervention is for pregnant people prescribed buprenorphine for the management of opioid use disorder. The intervention being studied is a brief therapy protocol and a mobile application. Participation involves four 60-minute therapy appointments during pregnancy, and four 30-minute therapy appointments at the end of pregnancy through 3 months postpartum. The mobile application will be accessible for at least the duration of the study. Participants will also be asked to complete questionnaires at enrollment and again at 1-month postpartum and 3-months postpartum, will send monthly photos of their prescription bottle/box, and will be contacted randomly throughout the study to perform a medication count. The total duration of the study is between 5-9 months depending on when you enroll (early second trimester-mid third trimester). Compensation is provided.
Stay on current meds
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Early Phase 1
Age:18 - 45
Sex:Female

26 Participants Needed

Why Other Patients Applied

"I've been struggling with alcoholism and depression on-and-off for about 12 years. I have heard of people have good outcomes for various mental health issues after using psilocybin but would not be willing to try it without a doctor's care. So I'm applying to a trial. "

QJ
Depression PatientAge: 60

"I've tried a number of antidepressants over the years and nothing has made a significant difference. I have a family history of alcohol use and I am interested to try ketamine."

YU
Anxiety PatientAge: 62

"I have been researching ketamine and I feel it would be a good fit. I'd like I try in a controlled environment. Plus I've been on the same drugs for years and I just feel stuck."

DJ
Anxiety PatientAge: 64

"Sertraline has only been somewhat helpful for managing my anxiety. I tried prescribed benzodiazepines in the past, but I didn't like the side effects (drowsiness, some memory loss). I'm hoping I'll benefit from this trial."

AT
Anxiety PatientAge: 34

"I’ve been having a lot of anxiety and memory fog. I had a baby 18 months ago, and my pregnancy was very hard. During that time, I was prescribed sertraline because it was the safest option during pregnancy. It had bad side effects. Since I had my baby, I've tried another drug, but I haven't really improved. It often feels like my head isn’t 100% here. I need to be fully myself because I have two kids to take care of, and I also want to go back to school. With my mind like this, I won’t be able to do it. Hoping for a new option."

OR
Anxiety PatientAge: 40
1. The aim of this study is to assess anxiety in pediatric patients preoperatively, perioperatively, and postoperatively and whether meditation reduces anxiety in the days before, during, and after the surgery. 2. The second aim of this study is to see if longitudinal meditation is associated with decreased postoperative pain by examining whether the group prescribed meditation has reduced pain medication intake, measured by the frequency of liquid analgesic medicine intake.

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased
Age:6 - 18

60 Participants Needed

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Anxiety clinical trials in South Carolina pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Anxiety clinical trials in South Carolina work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Anxiety trials in South Carolina 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in South Carolina for Anxiety is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in South Carolina several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Anxiety medical study in South Carolina?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Anxiety clinical trials in South Carolina?

Most recently, we added Technology-Enhanced Therapy for Opioid Use Disorder During Pregnancy, ENX-102 for Social Anxiety Disorder and Mobile TMS for Depression to the Power online platform.

What do the "Power Preferred" and "SuperSite" badges mean?

We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.

Which clinics have received Power Preferred and SuperSite awards recruiting for Anxiety trials in South Carolina?

The Anxiety clinics in South Carolina currently recognized as SuperSites are: CenExel iResearch Savannah in Savannah, Georgia

What is the best fix for anxiety?

There isn’t one magic “fix” for anxiety, but studies show that most people improve with either cognitive-behavioural therapy (CBT) and/or daily medication such as an SSRI or SNRI, chosen together with a qualified clinician. Adding regular exercise, mindfulness or breathing practice, good sleep and limiting caffeine or alcohol can boost results, so think of treatment as a toolbox—start with proven professional help (therapy and possibly medicine) and layer the healthy habits on top for longer-term control.

What does 333 mean for anxiety?

“333” is a fast grounding trick for sudden anxiety: look around and name three things you see, notice three sounds, then deliberately move three body parts (for example, roll your shoulders, wiggle your toes, stretch your fingers). Focusing on simple sights, sounds, and movements pulls your attention out of racing thoughts and signals your nervous system that you’re safe, which can ease the physical surge of anxiety for a few moments. Use it as a quick reset; if anxiety keeps returning or interferes with daily life, add longer-term strategies like CBT, exercise, or speaking with a healthcare professional.

Do anxiety bracelets really work?

Bracelets made of magnets, copper, crystals, or “negative ions” have not been proven to calm anxiety, but a band can still help if you use it as a cue to do something that does work—e.g., press an acupressure point, follow a paced-breathing vibration, or ground yourself with a quick mindfulness check (small studies of these techniques show temporary relief). In other words, the bracelet is a prompt, not the treatment; for lasting improvement pair that prompt with evidence-based care such as cognitive-behavioral therapy, relaxation training, or medication discussed with a healthcare professional.

Does gabapentin treat anxiety?

Gabapentin isn’t FDA-approved for any anxiety disorder, but doctors sometimes prescribe it “off-label” when standard options (talk therapy, SSRIs/SNRIs, or—short term—benzodiazepines) haven’t worked or can’t be used. Small studies suggest it can ease social or short-term situational anxiety at doses of about 900–2,400 mg a day, yet the evidence is modest and it can cause sleepiness, dizziness, and withdrawal if stopped abruptly. If you’re considering it, discuss with your clinician how its uncertain benefits, side-effects, and need for slow tapering stack up against better-studied treatments and non-drug approaches like cognitive-behavioral therapy.

What is the FDA approved device for anxiety?

Strictly speaking, the FDA has not “approved” any device just for anxiety; rather, it has cleared several prescription-only cranial electrotherapy stimulators (CES) through its 510-k process—including Alpha-Stim AID, Fisher-Wallace Stimulator, and Cervella—for short-term relief of anxiety (often along with insomnia or depression). These devices send a very mild electrical current through clips on the earlobes for about 20–60 minutes a day over several weeks, and their use should be discussed with a healthcare professional to be sure they’re safe and appropriate for you.

What drug is used in rapid relief of anxiety?

For symptoms that need relief within minutes to an hour, doctors usually prescribe a short-acting benzodiazepine such as lorazepam or alprazolam; these calm the nervous system quickly but can cause drowsiness and, with repeated use, dependence, so they are meant for short-term or “as-needed” use. Other fast options include the antihistamine hydroxyzine (works in ~30 min) or propranolol for one-time performance anxiety, while longer-term control is handled with medicines like SSRIs and therapy.

What are the 4 R's of anxiety?

Professionals usually mean one of two quick, four-step loops: 1) Recognize the anxious thought or body cue, Reassure yourself with realistic facts, Relax with slow breathing, then Refocus on your task; or 2) Relabel the thought as “just anxiety,” Re-attribute it to a misfiring alarm, Refocus on a chosen activity for a few minutes, and Re-value the thought as unimportant noise. Some wellness articles cite Rest, Relaxation, Replenish, Release, but that version is a general self-care checklist, not an in-the-moment anxiety technique.

What is intense therapy for anxiety?

“Intensive” therapy for anxiety is the same proven treatments (like CBT and exposure exercises) delivered in a much bigger dose—several hours a day for a short stretch—through formats such as weekend “boot-camps,” 3–5-day-a-week intensive outpatient programs, or brief residential stays. This immersive approach is used when anxiety is severe, hasn’t improved with weekly sessions, or rapid progress is needed, and studies show it can match or outperform standard once-a-week therapy. To explore it, ask your provider or insurer about clinics that offer “intensive CBT/ERP,” “IOP,” or “PHP” programs run by licensed anxiety specialists.

Can I live a long life with anxiety?

Yes. Large studies show that untreated, severe anxiety can slightly raise the risk of early death—mainly by increasing suicide risk and unhealthy behaviors—but the effect is small and is greatly reduced when the condition is recognized and treated. People who get evidence-based care (therapy, possible medication), stay active, avoid smoking/drugs, and keep regular medical check-ups typically live just as long as those without anxiety, so focusing on treatment and healthy routines is the key to a long life.

What is the 5 4 3 2 1 anxiety trick?

The 5-4-3-2-1 “grounding” trick is a rapid way to pull your mind out of racing thoughts: name five things you can see, four you can touch, three you hear, two you smell, and one you can taste, taking slow breaths as you go. Engaging each sense crowds out worry signals and anchors you in the present; repeat or shorten the list any time a panic spike or rumination hits. It’s a quick coping tool—helpful in the moment—but if anxiety is frequent or disabling, pair it with ongoing care from a mental-health professional.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security